News & Updates

Treatment with apremilast results in a significant reduction in genital psoriasis (G-PsO), as well as improvements in itch, pain, discomfort, redness, and quality of life (QoL), in patients with moderate-to-severe G-PsO who are intolerant to topical therapies, a study has shown.

Omalizumab scores in the NIH*-sponsored phase III OUtMATCH** trial, increasing the threshold for an allergic reaction to peanut and other common food allergens in children and adults with multiple food allergies.

Children whose mothers have atopic dermatitis (AD) are likely to develop the same disease, while some develop other allergic illness (OAI) first, reports a study. This suggests that not everyone will follow the same sequential pathway.